BIO CEO Advisory Committee
 |
Tom Brakel, MD Tom M. Brakel has been with Federated Kaufmann Funds since 2003 and has been a Portfolio Manager since 2009. Mr. Brakel focuses on security selection with particular emphasis in the health sector. Prior to the financial industry, Mr. Brakel spent five years at Organon Pharmaceuticals. Mr. Brakel earned an MD from Erasmus University, The Netherlands, and an MBA from Stanford University. |
 |
John Chambers John Chambers, a Managing Director and Head of Healthcare Investment Banking group, joined Roth Capital Partners in December 2009. Chambers was formerly the head of Merriman Curhan Ford’s Heath Care and investment banking team. Prior to joining Merriman, Chambers was co-head of investment banking at Rodman & Renshaw. He has also held senior-level health care and biotechnology banking positions at SG Cowen, Lehman Brothers, UBS and Salomon Smith Barney. Chambers has executed a significant number of banking transactions, strategic transactions and restructurings across all health care sectors. Chambers earned his MBA from Columbia Business School and his BS in mechanical engineering from Union College. |
 |
Michael Gilman, PhD Michael Gilman is Senior Vice President, Early-Stage Programs, at Biogen Idec, with responsibility for project teams managing the company’s development programs through clinical proof-of-concept. He joined Biogen Idec in March 2012 following its acquisition of Stromedix, a venture-backed company focused on fibrosis and organ failure, where Dr. Gilman was Founder and Chief Executive Officer. Prior to founding Stromedix in 2006, Dr. Gilman served as Executive Vice President, Research at Biogen Idec, with responsibility for the company’s discovery research activities in Cambridge and San Diego. From 1994 to 1999, Dr. Gilman was at ARIAD Pharmaceuticals, where he was Executive Vice President and Chief Scientific Officer. From 1986 to 1994, Dr. Gilman was on the scientific staff of Cold Spring Harbor Laboratory in New York, where his research focused on mechanisms of signal transduction and gene regulation. Dr. Gilman was a postdoctoral fellow at the Whitehead Institute. He holds a PhD in Biochemistry from University of California, Berkeley, and a SB in Life Sciences from Massachusetts Institute of Technology. Dr. Gilman currently serves on the on the Board of Directors of Via Science and the Scientific Advisory Board of Sangamo BioSciences. |
 |
Michael Hay Michael Hay, Vice President, Sagient Research Systems. Michael has been with Sagient for over eight years and has over 12 years of financial markets experience. He manages the BioMedTracker analyst team and serves as Vice President at Sagient, which was acquired by Informa in 2012. He is also responsible for product development, corporate planning and sales and marketing. Michael has consulted numerous top-tier pharmaceutical companies on strategic decisions as well as worked closely with top healthcare investment firms providing insight on investment and trading decisions. Michael served on the BIO CEO advisory board in 2012. Michael's financial markets career began at Thomson Financial in 2000. He reached the position of Manager, Capital Markets Intelligence and was directly responsible for corporate client relationships within the Technology sector. At Thomson he consulted senior management regarding shareholder composition, financial markets and competitive positioning. Michael received a Bachelor of Science degree in Finance from University of Colorado, Boulder. |
 |
Peter Kolchinksky, PhD Dr. Kolchinsky is a co-founder and General Partner of RA Capital Management, which has been investing in healthcare companies since 2002. He is a member of the National Academies Board on Global Science and Technology, authored an e-book titled “The Entrepreneur’s Guide to a Biotech Startup”, and serves as an advisor to startup companies and non-profits. Peter received his undergraduate degree in Biology from Cornell University and a Ph.D. in Virology from Harvard University, where he conducted research at Dana-Farber Cancer Institute on the entry mechanism of Human Immunodeficiency Virus (HIV). |
 |
Arlene Morris Arlene Morris was named CEO of Syndax in 2012 after working as a director of the company for nine months. Syndax Pharmaceuticals is a late-stage oncology company supported by top venture capitalists and led by industry experts developing treatments for large markets including metastatic breast and lung cancer. The company’s platform is based on employing epigenetics to overcome the problem of resistance in oncology care. Targeted therapies represent an important class of agents used to treat both breast and lung cancers based on blocking the tumor’s addiction to growth promoting signals. Prior to Syndax, Ms. Morris served as chief executive officer and member of the board of directors for Affymax, Inc., a biopharmaceutical company located in Palo Alto, Calif., which was spun out of GlaxoSmithKline (GSK) in 2001 to develop a pipeline of synthetic peptide-based drug candidates for the treatment of anemia in dialysis patients. During her eight years as president and CEO at Affymax, Ms. Morris led the company through the development of peginesatide (Omontys®), a strategic collaboration with Takeda and an Initial Public Offering of $90 million. She also raised private C and D rounds of $100 million. Prior to Affymax Ms. Morris was the president and CEO of Clearview Projects, an advisory firm which counseled biopharmaceutical and biotechnology companies on strategic transactions. Before that she was the senior vice president, business development at Coulter, a biotech company focused on immunotherapeutic approaches to cancer, autoimmune and infectious diseases, where she completed numerous transactions including a $1.0 billion merger between Corixa and Coulter. Ms. Morris began her career at Johnson & Johnson (J&J) as a sales representative rising to vice president of business development. In addition to Syndax, Ms. Morris serves on the board of directors of BIO, Neovacs, MediciNova and the Foundation for Research and Development, Medical University of South Carolina. She received her bachelor’s degree in biology and chemistry from Carlow College. |
 |
Oleg Nodelman Oleg Nodelman is the Founder and Managing Director of EcoR1 Capital, a San Francisco-based, value-oriented healthcare investment fund. EcoR1 capitalizes on opportunities in the biotechnology sector and mitigates risk through a highly engaged investment process, emphasizing the value of identifying and recruiting premier human capital in all aspects of corporate management and scientific leadership. Prior to EcoR1, Mr. Nodelman was a portfolio manager at BVF Partners L.P., one of the oldest dedicated biotechnology hedge funds. At BVF, Mr. Nodelman’s responsibilities included all aspects of the business including opportunity generation, deep diligence, portfolio management and trading. Prior to joining BVF in 2001, Mr. Nodelman was a consultant with Mercer Management Consulting (now Oliver Wyman), a consulting firm focused on strategy, operations, risk management, organizational transformation and leadership development. At Mercer, he worked with senior management from companies in a variety of industries to develop and implement long-term strategy and build shareholder value. Mr. Nodelman is on the Board of Addex Therapeutics (SIX: ADXN) and a is member of the President's Council at the Gladstone Institute. He holds a Bachelor of Science in Foreign Service with a concentration in Science and Technology from Georgetown University. |
 |
David Sable, MD David Sable, MD, directs healthcare and life science investing for the Special Situations Funds and is portfolio manager of the Special Situations Life Sciences Fund. After graduating from the Wharton School and the University of Pennsylvania School of Medicine, residency in obstetrics and gynecology at New York Hospital - Cornell Medical Center, fellowship at Brigham and Women's Hospital, and clinical practice at Harvard Medical School and MIT, he co-founded the Institute for Reproductive Medicine and Science at Saint Barnabas Medical Center in New Jersey. He subsequently founded Assisted Reproductive Medical Technologies, which was acquired in 2000. After leaving clinical medicine at age 43, Dr. Sable managed a proprietary healthcare portfolio at Deutsche Bank before joining the Special Situations group. Dr. Sable is an adjunct in the department of biology at Columbia University, and teaches “Entrepreneurship in Biotechnology” at Columbia’s Graduate School of Arts and Sciences, has lectured on healthcare investing, policy, and biotechnology business development at the Wharton School, NYU, Rockefeller University and Rutgers; has delivered keynote addresses to the American Fertility Society, the Texas Fertility Society and the Mexican Fertility Society; and appeared on the CBS Morning News, ABC World News Tonight, NY1 News and PBS’ Nova. In addition to his academic publications, he has written for the Newark Star-Ledger, Yoga Journal, Genetic Engineering and Biotechnology News, Xconomy, Nature Biotechnology, and the Columbia Spectator. |
 |
Joel Sendek Joel Sendek is a Managing Director and Biotechnology Analyst at Stifel, Nicolaus & Company. He is also Group Head of the Healthcare Equity Research at Stifel. He has been a senior biotechnology analyst for 15 years with coverage that spans both large-cap and small-cap companies. Prior to joining Stifel, Joel was a Managing Director and biotechnology analyst for 11 years at Lazard Capital Markets, where he established Lazard's healthcare equity research effort in 2000. Prior to Lazard he was a Senior Vice President and biotechnology research analyst at Gerard Klauer Mattison. He has been recognized by the Wall Street Journal as an All-Star Analyst with a #1 ranking for stock picking in biotechnology as well as first place in the "Home Run Hitter" category among all sectors. From 1992 to 1997, Joel served as Senior Director of Corporate Development at Progenics Pharmaceuticals, where he negotiated corporate partnerships, raised private equity capital and prepared the company for an IPO. Prior to Progenics, he worked in the corporate finance department at Goldman, Sachs & Co., focused on healthcare, from 1989 to 1992. Joel received a Bachelor of Arts in Biochemistry from Rice University. |
 |
Nathan Tinker, PhD Nathan Tinker is Executive Director of the New York Biotechnology Association (NYBA), the statewide trade association representing New York’s bioscience community. As Executive Director, Dr. Tinker serves as a spokesman and advocate for the state’s industry. NYBA supports the development and growth of New York State's biotechnology industry, and serves its members and the biotechnology community by providing a network for information exchange, shared services, and collective action. Dr. Tinker comes to NYBA with a deep knowledge and awareness of the industry and its unique strengths in New York. He has more than 15 years of experience in working with both global and emerging technology companies. Immediately prior to joining NYBA, Dr. Tinker served as Executive Director of the Sabin Vaccine Institute Cancer Vaccine Consortium and as a Director of the Nanotechnology and Biotechnology Practice at Antenna Group, a boutique communications firm. Before that, Nathan was Co-Founder and Executive Vice President of the NanoBusiness Alliance, the national trade association for nanotechnology. Dr. Tinker began his career in market research and communications, serving such clients as Apple, eSpeed, Sprint, Cantor Fitzgerald, DaimlerChrysler, Yahoo!, CSX, and many others. Dr. Tinker lends his talent and knowledge to industry on corporate boards, including the advisory boards of Physicians Interactive Holdings, Viral Genetics, Versilant Technologies and Namar Consulting, as well as with non-profit groups, including Nanotechnology Commercialization Association and the Kingsborough College Bioscience Advisory Committee. |
